Lung Adenocarcinoma

BISDA displayed 48-h IC50 of 2.609 µg mL-1 in A549 cells, decreased viability compared to controls, and was less toxic than cisplatin while inducing apoptosis, G2/M cell cycle arrest, and inhibiting cancer cell migration...Principal component analysis showed that BISDA reprogrammed signaling through decoupling of the EGFR-mTOR axis from the TGFβ-AKT1-MAPK3-HSP90 cluster, indicative of a global rewiring of pathways. These results suggest that BISDA may serve as a multifaceted inhibitor for treating LUAD, acting in an antiproliferative capacity through apoptosis induction while also preventing signaling pathways associated with resistance.

Mechanistically, MCM7 regulates pyrimidine synthesis enzymes (DHODH and UMPS), activates the ERK pathway, and interacts with the MIF-CD74 axis. These findings indicate that MCM7 serves as a critical link connecting pyrimidine metabolic reprogramming to the regulation of the TIME in LUAD.

She was treated with tarlatamab, achieving 4 months of treatment response with symptomatic relief and improved performance status. This case represents the first documented evidence of the clinical benefit of tarlatamab in transformed SCLC and highlights its therapeutic potential in this challenging setting.

First-line Osimertinib induced a dramatic clinical and radiological response within days...This case underscores the critical difficulty of diagnosing lepidic-patterned tumors in an oncological emergency. It highlights the necessity of a multidisciplinary approach, combining cytology, radiology, and early molecular testing as a surrogate for traditional histopathology to guide urgent targeted therapy.

Importantly, the MPO+SPHK1+/ASPM+ myeloid compartment was significantly enriched in anti-PD-1 non-responders (P < 0.05). Our study establishes a calcium signaling-based prognostic signature, uncovers myeloid SPHK1/ASPM as drivers of immunosuppression, and provides a potential biomarker for immunotherapy stratification.

We report a 69-year-old man with resectable stage IIB right upper lobe lung adenocarcinoma who received neoadjuvant pembrolizumab, carboplatin, and pemetrexed followed by robotic-assisted lobectomy. He received adjuvant pembrolizumab and daratumumab-CyBorD with partial hematologic response. This case highlighted that amyloid can unexpectedly be a second diagnosis after post-neoadjuvant lung resections and that proteomic subtyping is essential for prompt haematologic staging and treatment.

The model was further validated in an independent external cohort (n = 80), showing an AUC of 0.940. In conclusion, a model integrating maximum tumor diameter, tumor differentiation, number of lymph node dissections, and pleural invasion effectively predicts recurrence risk after thoracoscopic resection in Stage I a lung adenocarcinoma, facilitating individualized treatment planning.

In conclusion, extracranial metastasis, PLR and ECOG PS were identified to be prospective independent clinical prognostic indicators of survival in patients with lung adenocarcinoma and LM. Overall, the present study highlighted the potential use of clinical characteristics and hematological variables before treatment to predict the outcomes of patients with lung adenocarcinoma complicated with LM.

In vivo, exosomal NEAT1 promoted tumor growth in DDP-treated xenografts, while NEAT1 knockdown reversed this effect and restored p53 pathway activity. Collectively, our work unveils a novel TAM-exosome-NEAT1-MAD1L1/p53 signaling axis that drives cisplatin resistance in lung adenocarcinoma, highlighting NEAT1 and its intercellular delivery as potential therapeutic targets to overcome chemoresistance.

Furthermore, consensus clustering analysis successfully partitioned LUAD into two molecular subtypes exhibiting immune heterogeneity. The prognostic model constructed based on epithelial cell-specific genes associated with histidine metabolism effectively distinguishes LUAD patients and their immune characteristics, revealing epithelial cells as a key cell population regulating LUAD histidine metabolism.

The HEATR5B-ALK fusion is targetable by ensartinib, producing durable disease control and excellent tolerability. Comprehensive NGS and ALK IHC are essential for detecting rare actionable ALK variants.

This report adds an insight into the involvement of genetic events in histological transformation in EGFR-mutated lung cancer.